Statements (55)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Antihero
|
gptkbp:approves |
gptkb:1954
gptkb:FDA |
gptkbp:atccode |
B01 AA03
|
gptkbp:available_on |
generic drug
|
gptkbp:brand |
gptkb:Coumadin
gptkb:Jantoven |
gptkbp:casnumber |
81-81-2
|
gptkbp:chemical_formula |
C19 H16 O4
|
gptkbp:contraindication |
pregnancy
severe liver disease active bleeding |
gptkbp:developed_by |
gptkb:Merck_&_Co.
|
gptkbp:dosage_form |
gptkb:tablet
injection 2-10 mg daily |
https://www.w3.org/2000/01/rdf-schema#label |
warfarin
|
gptkbp:interacts_with |
NSAIDs
antibiotics antifungals certain herbal supplements |
gptkbp:is_monitored_by |
INR (International Normalized Ratio)
|
gptkbp:mechanism_of_action |
inhibits vitamin K epoxide reductase
|
gptkbp:patient_education |
report any unusual bleeding
avoid foods high in vitamin K inform healthcare providers about use monitor INR regularly |
gptkbp:pharmacokinetics |
highly protein-bound
metabolized by liver oral administration anticoagulant effect delayed onset of action |
gptkbp:related_to |
gptkb:Cardiology
gptkb:deep_vein_thrombosis gptkb:atrial_fibrillation anticoagulation therapy thrombosis vitamin K pulmonary embolism stroke prevention embolism blood thinner |
gptkbp:side_effect |
nausea
bruising bleeding hair loss skin necrosis |
gptkbp:used_for |
preventing blood clots
treating deep vein thrombosis treating pulmonary embolism preventing stroke in patients with atrial fibrillation |
gptkbp:bfsParent |
gptkb:ketoconazole
gptkb:pharmaceuticals gptkb:rifampicin |
gptkbp:bfsLayer |
4
|